"I think that the amount of benefit they’ll get in continuing will be small enough that that would be a perfectly rational decision. An additional one-third reduction in a very small risk is still a very small benefit," Dr. Ravdin observed.
Simultaneous with Prof. Gray’s presentation in San Antonio, the ATLAS results were published online (Lancet 2012 Dec. 5 [doi: 10.1016/S0140-6736(12)61963-1]).
The ATLAS trial was funded by Cancer Research UK, the UK Medical Research Council, AstraZeneca, the U.S. Army, and EU Biomed. Dr. Gray reported having no financial conflicts.